Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 22 06 2021
revised: 05 10 2021
accepted: 15 11 2021
pubmed: 24 11 2021
medline: 19 2 2022
entrez: 23 11 2021
Statut: ppublish

Résumé

Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF)

Identifiants

pubmed: 34810201
pii: 0008-5472.CAN-21-1991
doi: 10.1158/0008-5472.CAN-21-1991
pmc: PMC8770597
mid: NIHMS1759764
doi:

Substances chimiques

Core Binding Factor Alpha 1 Subunit 0
NOTCH1 protein, human 0
NOTCH2 protein, human 0
Notch1 protein, mouse 0
Notch2 protein, mouse 0
RUNX2 protein, human 0
Receptor, Notch1 0
Receptor, Notch2 0
Runx2 protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-263

Subventions

Organisme : NCI NIH HHS
ID : K08 CA222657
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Sci Adv. 2021 Jan 29;7(5):
pubmed: 33514539
Sci Adv. 2020 Sep 23;6(39):
pubmed: 32967837
Cancer Cell. 2020 Jul 13;38(1):60-78.e12
pubmed: 32473656
Cell. 2019 Oct 3;179(2):403-416.e23
pubmed: 31585080
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93
pubmed: 25267614
J Exp Med. 2019 Mar 4;216(3):674-687
pubmed: 30737256
Cancer Res. 2001 Apr 1;61(7):3200-5
pubmed: 11306509
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Cancer Res. 2010 May 15;70(10):3877-83
pubmed: 20406986
Nat Med. 2018 Aug;24(8):1143-1150
pubmed: 30038220
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98
pubmed: 23307984
Cell Rep. 2016 Aug 2;16(5):1259-1272
pubmed: 27452466
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Mol Oncol. 2021 Jan;15(1):195-209
pubmed: 33084222
Cancer Discov. 2021 Aug;11(8):1952-1969
pubmed: 33707236
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
Genes Dev. 2016 Jun 1;30(11):1289-99
pubmed: 27298335
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Mol Cell Biol. 2002 May;22(9):3129-39
pubmed: 11940670
Biochem Biophys Res Commun. 2019 Jul 12;515(1):214-221
pubmed: 31146914
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
J Cell Biochem. 2010 Apr 1;109(5):992-9
pubmed: 20082318
Cancer Discov. 2020 Jan;10(1):26-39
pubmed: 31852718
Genes Dev. 2018 Jul 1;32(13-14):915-928
pubmed: 29945888
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
J Thorac Oncol. 2020 Dec;15(12):1823-1835
pubmed: 33011388
Sci Signal. 2019 Feb 05;12(567):
pubmed: 30723171
Genes Dev. 2021 Jun;35(11-12):847-869
pubmed: 34016693
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Genes Dev. 2019 Dec 1;33(23-24):1718-1738
pubmed: 31727771
J Thorac Oncol. 2015 Apr;10(4):553-64
pubmed: 25675280
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):705-10
pubmed: 24374627
Clin Cancer Res. 2020 Jul 15;26(14):3649-3661
pubmed: 32241817
Nature. 2017 May 18;545(7654):360-364
pubmed: 28489825
Cancer Cell. 2011 Feb 15;19(2):244-56
pubmed: 21316603
Development. 2007 Mar;134(6):1161-9
pubmed: 17332535
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Cancer Res. 2009 Feb 1;69(3):845-54
pubmed: 19176379
Nat Commun. 2021 Jun 23;12(1):3880
pubmed: 34162872
Cancer Cell. 2019 Jul 8;36(1):17-34.e7
pubmed: 31287989
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Genome Biol. 2020 Feb 7;21(1):32
pubmed: 32033573
Blood. 2006 Nov 15;108(10):3329-34
pubmed: 16888092
Nucleic Acids Res. 2017 Jan 4;45(D1):D658-D662
pubmed: 27789702

Auteurs

Deli Hong (D)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Erik H Knelson (EH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yixiang Li (Y)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yavuz T Durmaz (YT)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Wenhua Gao (W)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Emily Walton (E)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Amir Vajdi (A)

Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Tran Thai (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Maura Sticco-Ivins (M)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Amin H Sabet (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Kristen L Jones (KL)

Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Anna C Schinzel (AC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Rod T Bronson (RT)

Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.

Quang-De Nguyen (QD)

Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Michael Y Tolstorukov (MY)

Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Marina Vivero (M)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Sabina Signoretti (S)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

David A Barbie (DA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Matthew G Oser (MG)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Matthew_Oser@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH